Citi Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $60
Citi analyst Yigal Nochomovitz maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and maintains the target price at $60.According to TipRanks data, the analyst has a success rate of 45.4%
Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $46
Piper Sandler analyst Biren Amin maintains $Apellis Pharmaceuticals(APLS.US)$ with a hold rating, and maintains the target price at $46.According to TipRanks data, the analyst has a success rate of 42
Piper Sandler Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Apellis Pharmaceuticals (APLS) and EDAP TMS (EDAP)
Buy Rating Affirmed on Apellis Pharmaceuticals Amid Promising Pegcetacoplan Trials and Expert Optimism
Jefferies Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $80
Jefferies analyst Akash Tewari maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 59.5%
Jefferies Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second
Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights
Across the recent three months, 12 analysts have shared their insights on Apellis Pharmaceuticals (NASDAQ:APLS), expressing a variety of opinions spanning from bullish to bearish.The table below
Express News | Goldman Sachs Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $77
Apellis Pharmaceuticals (NASDAQ:APLS) Shareholders Are up 9.8% This Past Week, but Still in the Red Over the Last Year
Investing in stocks comes with the risk that the share price will fall. And unfortunately for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shareholders, the stock is a lot lower today than it was a
Analysts Conflicted on These Healthcare Names: Cardinal Health (CAH) and Apellis Pharmaceuticals (APLS)
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
Late-breaking presentation shows SYFOVRE (pegcetacoplan injection) demonstrated visual function benefit on prespecified endpoint in GALE long-term extension studyWALTHAM, Mass., July 09, 2024 (
Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
Apellis Pharmaceuticals’ (APLS Quick QuoteAPLS - Free Report) marketed portfolio comprises two drugs — Empaveli (pegcetacoplan) and Syfovre (pegcetacoplan injection).
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $49
Mizuho Securities analyst Graig Suvannavejh maintains $Apellis Pharmaceuticals(APLS.US)$ with a hold rating, and adjusts the target price from $52 to $49.According to TipRanks data, the analyst has a
Express News | Apellis Pharmaceuticals Inc : Mizuho Cuts Target Price to $49 From $52
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $82
BofA Securities analyst Tazeen Ahmad maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and maintains the target price at $82.According to TipRanks data, the analyst has a success rate of
Sector Update: Health Care Stocks Edge Higher in Afternoon Trading
Health care stocks were edging up Friday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) up less than 0.1%. The iShares Biotechnology ETF (IBB)
Express News | Baird Maintains Outperform on Apellis Pharmaceuticals, Maintains $100 Price Target
Apellis Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 161.03% Baird $100 → $100 Maintains Outperform 05/31/2024 20.07% Piper Sandler → $46 Initiates